Heron Therapeutics Inc. (NASDAQ:HRTX) shares saw unusually-high trading volume on Wednesday . Approximately 370,001 shares were traded during mid-day trading, a decline of 17% from the previous session’s volume of 445,515 shares.The stock last traded at $17.66 and had previously closed at $17.97.

HRTX has been the topic of several analyst reports. Leerink Swann restated a “buy” rating on shares of Heron Therapeutics in a research note on Monday, June 27th. Cantor Fitzgerald reiterated a “buy” rating and issued a $41.00 price objective on shares of Heron Therapeutics in a report on Friday, June 24th. Brean Capital reiterated a “buy” rating and issued a $55.00 price objective on shares of Heron Therapeutics in a report on Friday, May 6th. Jefferies Group reiterated a “buy” rating on shares of Heron Therapeutics in a report on Thursday, April 28th. Finally, Noble Financial reiterated a “buy” rating and issued a $51.00 price objective on shares of Heron Therapeutics in a report on Wednesday, April 20th. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $51.50.

The stock’s 50-day moving average is $18.90 and its 200 day moving average is $20.09.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.92). On average, equities analysts expect that Heron Therapeutics Inc. will post ($3.57) EPS for the current fiscal year.

In other Heron Therapeutics news, President Robert Rosen sold 200,000 shares of the company’s stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $23.23, for a total transaction of $4,646,000.00. Following the sale, the president now directly owns 178,968 shares of the company’s stock, valued at $4,157,426.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

A number of hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System raised its stake in Heron Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 54,211 shares of the biotechnology company’s stock valued at $1,447,000 after buying an additional 1,000 shares during the period. GAM Holding AG raised its position in shares of Heron Therapeutics by 28.9% in the fourth quarter. GAM Holding AG now owns 41,900 shares of the biotechnology company’s stock valued at $1,119,000 after buying an additional 9,400 shares during the last quarter. Brown Advisory Inc. raised its position in shares of Heron Therapeutics by 4.8% in the fourth quarter. Brown Advisory Inc. now owns 300,941 shares of the biotechnology company’s stock valued at $8,036,000 after buying an additional 13,651 shares during the last quarter. Russell Frank Co raised its position in shares of Heron Therapeutics by 46.9% in the fourth quarter. Russell Frank Co now owns 48,830 shares of the biotechnology company’s stock valued at $1,369,000 after buying an additional 15,585 shares during the last quarter. Finally, Turner Investments L.P. raised its position in shares of Heron Therapeutics by 19.7% in the fourth quarter. Turner Investments L.P. now owns 106,080 shares of the biotechnology company’s stock valued at $2,832,000 after buying an additional 17,470 shares during the last quarter.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.